Skip to main content

Day: April 24, 2020

Orange: Combined Ordinary and Extraordinary Shareholders’ Meeting of May 19st, 2020

Press releaseParis, April 24, 2020Combined Ordinary and Extraordinary Shareholders’ Meeting of       May 19st, 2020Details concerning the availability of information on the Combined Ordinary and Extraordinary Shareholders’ MeetingExceptionally, due to the Covid-19 pandemic and by application of ordinance no. 2020-321 of 25 March 2020, the Combined Ordinary and Extraordinary Shareholders’ Meeting will be held behind closed doors at Orange’s corporate headquarters, 78 rue Olivier de Serres, 75015 Paris, at 4pm, without the physical presence of shareholders or any other person who would otherwise have the right to attend.The meeting notices were published in the February 21th and April 24th 2020 issues of the French Bulletin des Annonces Légales Obligatoires (BALO).All documents and information specified in article R. 225-83 of the French...

Continue reading

Orange: Assemblée Générale Mixte du 19 mai 2020

Communiqué de presseParis, le 24 avril 2020Assemblée Générale Mixte du 19 mai 2020Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée générale mixte des actionnairesEn raison de l’épidémie de covid-19 et en application, à titre exceptionnel, de l’ordonnance n° 2020-321 du 25 mars 2020, l’Assemblée générale mixte des actionnaires d’Orange se tiendra à huis clos au siège social d’Orange, 78 rue Olivier de Serres, 75015 Paris, le 19 mai 2020 à 16h00, sans que les actionnaires et les autres personnes ayant le droit d’y assister ne soient présents physiquement.L’avis préalable de réunion et l’avis de convocation de l’Assemblée ont été publiés au Bulletin des Annonces Légales Obligatoires (BALO) respectivement le 21 février et le 24 avril 2020.L’ensemble des documents et renseignements mentionnés à l’article...

Continue reading

Innate Pharma Files Its 2019 Universal Registration Document (Document d’enregistrement universel) and Its 2019 Annual Report on Form 20-F

MARSEILLE, France, April 24, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2019 Universal Registration Document (Document d’enregistrement universel) for the year ended December 31, 2019 with the French market authority “Autorité des Marchés Financiers” (“AMF”). It can be consulted and downloaded (in French) on the Company’s website (https://investors.innate-pharma.com/regulated-information/financial-reports) and on the AMF’s website (www.amf-france.org).The Company also announced today the filing of its annual report on Form 20-F for the year ended December 31, 2019 with the United States Securities and Exchange Commission (“SEC”). It can be consulted and downloaded on the Company’s website (https://investors.innate-pharma.com/regulated-information/financial-reports)...

Continue reading

Innate Pharma Files Its 2019 Universal Registration Document (Document d’Enregistrement Universel) and Its 2019 Annual Report on Form 20-F

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2019 Universal Registration Document (Document d’enregistrement universel) for the year ended December 31, 2019 with the French market authority “Autorité des Marchés Financiers” (“AMF”). It can be consulted and downloaded (in French) on the Company’s website (https://investors.innate-pharma.com/regulated-information/financial-reports) and on the AMF’s website (www.amf-france.org).The Company also announced today the filing of its annual report on Form 20-F for the year ended December 31, 2019 with the United States Securities and Exchange Commission (“SEC”). It can be consulted and downloaded on the Company’s website (https://investors.innate-pharma.com/regulated-information/financial-reports) and on...

Continue reading

Innate Pharma Publie Son Document d’Enregistrement Universel 2019 Et Son Rapport Annuel 2019 Sur « Form 20-F »

Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce que son Document d’enregistrement universel pour l’année 2019 a été déposé auprès de l’Autorité des marchés financiers (« AMF ») le 24 avril 2020. Il peut être consulté et téléchargé à partir du site Internet de la Société (www.innate-pharma.com/fr, rubrique Investisseurs / Information réglementée et publications) ou sur le site Internet de l’AMF (www.amf.org).Les documents suivants sont intégrés dans le Document d’enregistrement universel :le rapport financier annuel 2019,le rapport de gestion 2019,le rapport sur le gouvernement d’entreprise prévu à l’article L. 225-37 du Code de commerce,les rapports des commissaires aux comptes.Innate annonce également que son rapport annuel sur Form 20-F pour l’année 2019 (en langue...

Continue reading

Notice by Aspo to redeem its outstanding capital securities issued in 2016

ASPO Plc  INSIDE INFORMATION     April 24, 2020 at 5:30 p.m.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Notice by Aspo to redeem its outstanding capital securities issued in 2016Aspo Plc (“Aspo” or the “Company”) announces that it will exercise its right to redeem its outstanding EUR 6.6 million 6.750 percent capital securities issued on May 27, 2016 (ISIN: FI4000210240) (the “2016 Capital Securities”) which were not purchased in the voluntary cash tender offer.The outstanding EUR 6.6 million 2016 Capital Securities will be redeemed in full on May 27, 2020 in accordance with the terms and conditions of the 2016 Capital Securities...

Continue reading

Aspo ilmoittaa lunastavansa jäljellä olevan vuonna 2016 liikkeeseenlasketun hybridilainan

ASPO Oyj         Sisäpiiritieto          24.4.2020 klo 17.30EI JULKAISTAVAKSI TAI LEVITETTÄVÄKSI, SUORAAN TAI VÄLILLISESTI YHDYSVALLOISSA, AUSTRALIASSA, KANADASSA, HONGKONGISSA, JAPANISSA, UUDESSA-SEELANNISSA, SINGAPORESSA TAI ETELÄ-AFRIKASSA TAI SELLAISISSA MUISSA MAISSA TAI TÄLLAISIIN MAIHIN, JOISSA LEVITTÄMINEN TAI JULKAISEMINEN OLISI LAINVASTAISTA.Aspo ilmoittaa lunastavansa jäljellä olevan vuonna 2016 liikkeeseenlasketun hybridilainanAspo Oyj (”Aspo” tai ”Yhtiö”) ilmoittaa käyttävänsä oikeuttaan lunastaa 27.5.2016 liikkeeseen laskeman ja jäljellä olevan 6 600 000 euron ja 6,750 prosentin korkoisen hybridilainan (ISIN: FI4000210240) (”2016 Hybridilaina”), jota ei ostettu vapaaehtoisessa käteisostotarjouksessa.Jäljellä oleva 6 600 000 euron osuus 2016 Hybridilainoista lunastetaan täysimääräisesti 2016 Hybridilainan ehtojen mukaisesti...

Continue reading

GROUPE GUILLIN : AVIS PREALABLE A L’AGM DU 12 JUIN 2020

GROUPE GUILLINSociété Anonyme au capital de 11 487 825 eurosSiège social : Zone Industrielle – Avenue du Maréchal de Lattre de Tassigny25290 ORNANS349 846 303 RCS BESANCON(la « Société »)AVIS PREALABLE A L’ASSEMBLEE GENERALE MIXTEDU 12 JUIN 2020Les actionnaires de la Société sont informés qu’ils seront réunis en Assemblée Générale Mixte le 12 juin 2020 à 9 heures 30 au siège social à Ornans (25290), Zone Industrielle, Avenue du Maréchal de Lattre de Tassigny, à l’effet de statuer sur l’ordre du jour ci-après.

Continue reading

Conditions for Riksbank Bid Procedures Municipal Bonds

Sveriges RiksbankBid procedure details Municipal Bonds, 2020-04-28    Settlement date 2020-04-30Bids have to be entered by 10.00 on APR 28, 2020Highest permitted bid volume: 1 000 SEK million in issue 2206, 2311, 2505, and 2611.Lowest permitted bid volume: 50 SEK millionBids only through counterparties approved by the RiksbankRESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON APR 28, 2020     For more information, please contact:Trading desk at the Riksbank+ 46 8 696 6970General and special terms and conditions can be retrieved at http://www.riksbank.se

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.